# Hangzhou Sciwind Biosciences Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-sciwind-biosciences-co

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Website: www.sciwind.com.cn
- Total disclosed funding: $138M
- Latest round: Series C (Oct 11, 2021)
- Investors on record: 8

## About

Based in China, Sciwind Biosciences develops and commercializes innovative biopharmaceuticals, focusing on therapeutic solutions for metabolic diseases and diabetes management.Founded in 2017 and headquartered in Hangzhou, China, Sciwind Biosciences is dedicated to the development of therapies targeting metabolic disorders. The company has successfully completed 5 deals, with the most recent funding round occurring on October 11, 2021. The latest investment came through a Series C funding round, where Sciwind raised CNY 450 million from investors including IDG Capital, LYFE Capital, Loyal Valley Capital, and Zhengxingu Capital. The company is led by CEO Hai Pan, whose previous entrepreneurial experience contributes to Sciwind's strategic direction.Sciwind Biosciences specializes in creating and commercializing biopharmaceuticals, particularly concentrating on therapeutic solutions for metabolic diseases, including non-alcoholic steatohepatitis (NASH). The company's primary offerings are GLP-1 receptor agonists, designed to improve glycemic control for patients with Type 2 diabetes by mimicking GLP-1 hormone activity. Their products primarily serve healthcare providers and institutions that manage diabetes and metabolic diseases, focusing on the Chinese market while planning expansion into other regions as regulatory approvals are secured.Sciwind's revenue model is based on B2B partnerships with healthcare institutions, hospitals, and pharmaceutical distributors. These entities procure GLP-1 therapeutics in bulk to serve their patient populations. The pricing aligns with industry standards for biopharmaceuticals, reflecting the costs of developing their innovative drug offerings. Strategic alliances with research institutions or pharmaceutical companies further enhance Sciwind's market presence and ensure wider distribution of its products.In October 2021, Hangzhou Sciwind Biosciences Co., Ltd. raised CNY 450 million in Series C funding to advance the clinical development of its proprietary GLP-1 receptor agonism candidates. The company anticipates significant milestones from their lead programs, including XW003, XW004, and XW014. Sciwind aims to expand its product lineup and is actively exploring new markets, particularly targeting regions where regulatory approvals will allow further penetration. The recent funding will support these initiatives, positioning Sciwind for enhanced growth and expansion in the biopharmaceutical landscape.

## Funding rounds

- Series C, Oct 11, 2021, $70M — IDG Capital, LYFE Capital, Loyal Valley Capital, Zhengxingu Capital
- Series B, Feb 19, 2021, $39M — Legend Capital, Haibang Venture, LYFE Capital
- Series A, Feb 13, 2019, $30M — Legend Capital, Kawin Technology, Shiyu Capital
- Angel, Dec 11, 2017 — Shiyu Capital

## Investors

- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Angel, Series A
- Legend Capital — Series A, Series B
- Kawin Technology — Series A
- Haibang Venture — Series B
- LYFE Capital — Series B, Series C
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series C
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series C
- Zhengxingu Capital — Series C